Navigation

Colorectal cancer (first line) - cetuximab

Cetuximab for the first line treatment of metastatic colorectal cancer

Status: History
Expected date of issue: August 2009
Referral date: December 2007
Process: STA
Topic area:
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Helen Knight
Communications manager: Alice Law
Project manager: Jeremy Powell
Assessment Group / Evidence Review Group: West Midlands Health Technology Assessment Collaboration
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 08 April 2008
1st appraisal committee meeting: 03 September 2008
2nd appraisal committee meeting 04 November 2008
3rd appraisal committee meeting: 06 January 2009
4th appraisal committee meeting: 01 April 2009
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers / Sponsors

  • Merck-Serono (cetuximab)

 

Patient / Carer Groups

  • Beating Bowel Cancer
  • Bowel Cancer UK
  • Macmillan Cancer Relief

 

Professional Groups

  • Association of Coloproctology of Great Britain and Ireland
  • British Association of Surgical Oncology
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • UK Oncology Nursing Society

 

Others

  • Department of Health
  • Islington PCT
  • Nottinghamshire County PCT
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

 

Possible comparator manufacturer(s)

  • Mayne Pharma plc (calcium folinate, fluorouracil, oxaliplatin)(declined to participate)
  • Medac (UK) (disodium folinate, fluorouracil)(CA&U not returned, not participating)
  • Merck-Serono (tegafur with uracil)
  • Pfizer Ltd (irinotecan)
  • Roche Diagnostics
  • Roche Products Ltd (capecitabine)
  • Sanofi-Aventis Ltd (oxaliplatin)
  • Teva UK (calcium folinate)(CA&U not returned, not participating)
  • Wockhardt UK (calcium folinate, fluorouracil)(CA&U not returned, not participating)
  • Wyeth Pharmaceuticals (calcium levofolinate) (declined to participate)

 

Relevant research group

  • Institute of Cancer Researchs

 

Evidence Review Group

  • National Institute for Health Research Health Technology Assessment Programme
  • West Midlands Health Technology Assessment Collaboration (WMHTAC)

 

Associated Guideline Groups

  • National Collaborating Centre for Cancer

 

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
11 March 2008 Final scope re-issued due to anticipated change in licence
19 May 2008 First committee meeting delayed until 3 September 2008
20 November 2008 The Committee was not in a position to decide on a final appraisal determination because it needed further exploration of the consultation responses received. The Committee will reconvene to discuss this topic at its next meeting on 6 January 2009.
Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.